Abstract
Objective
We have noted an increased number of cases of vertebral osteomyelitis secondary to Candida species over the past few years at our facility. Our aim was to identify and review these cases to elucidate risk factors, treatment regimens and outcomes.
Methods
We performed a retrospective chart review using our electronic medical record and microbiology laboratory database to identify cases of vertebral osteomyelitis due to Candida at a single teaching hospital from 2006–2018.
Results
We found 15 cases of Candida vertebral osteomyelitis. The majority of cases were due to Candida albicans and affected either the lumbar or the thoracic spine. Injection drug use and previous spine surgery were the two most common risk factors identified. Treatment was largely with intravenous antifungal induction followed by prolonged therapy with oral fluconazole. There was no short-term mortality though we lacked long-term follow-up on most patients.
Conclusions
The number of vertebral infections due to Candida may be increasing. This may be partially driven by both a rise in intravenous drug use as well as the growing rate of spine surgery. Management following currently available guidelines seems favorable, though further studies are necessary to determine the optimal treatment regimen.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Miller DJ, Mejicano GC. Vertebral osteomyelitis due to candida species: case report and literature review. Clin Infect Dis. 2001;33:523–30.
Gamaletsou MN, Kontoyiannis DP, Sipsas NV, et al. Candida osteomyelitis: analysis of 207 pediatric and adult cases (1970–2011). Clin Infect Dis. 2012;55(10):1338–51.
Hendrickx L, Van Wijingaerden E, Samson I, Peetermans WE. Candidal vertebral osteomyelitis: report of 6 patients, and a review. Clin Infect Dis. 2001;32:527–33.
National Institute on Drug Abuse. West Virginia opioid summary. NIDA. http://www.drugabuse.gov/drugs-abuse/opioids/opioid-summaries-by-state/west-virginia-opioid-summary. Accessed 28 Feb 2018.
Pappas PG, Kauffman CA, Andes DR, et al. Clinical practice guideline for the management of candidiasis: 2016 update by the Infectious Diseases Society of America. Clin Infect Dis. 2016;62(4):e1–50.
Berbari EF, Kanj SS, Kowalski TJ, et al. 2015 Infectious Diseases Society of America clinical practice guidelines for the management of native vertebral osteomyelitis. Clin Infect Dis. 2015;61(6):e26–46.
Cone LA, Byrd RG, Potts BE, Wuestoff M. Diagnosis and treatment of candida vertebral osteomyelitis: clinical experience with a short course of therapy of amphotericin B lipid complex. Surg Neurol. 2004;62:234–7.
Storm L, Lausch KR, Arendrup MC, et al. Vertebral infection with candida albicans failing caspofungin and fluconazole combination therapy but successfully treated with high dose liposomal amphotericin B and flucytosine. Med Mycol Case Rep. 2004;6:6–9.
Friedman BC, Simon GL. Candida vertebral osteomyelitis: report of three cases and a review of the literature. Diagn Microbiol Infect Dis. 1987;8:31–6.
Gafter-Gvili A, Vidal L, Goldberg E, Leibovici L, Paul M Treatment of invasive candidal infections: systematic review and meta-analysis. Mayo Clin Proc. 2008; 83(9):1011
Funding
None.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors have no competing interest.
Ethical approval
West Virginia University Institutional Review Board approved this study.
Informed consent
No informed consent was required due to the retrospective nature of this study and no patient identifying information was utilized in this publication.
Rights and permissions
About this article
Cite this article
McLeod, N., Fisher, M. & Lasala, P.R. Vertebral osteomyelitis due to Candida species. Infection 47, 475–478 (2019). https://doi.org/10.1007/s15010-019-01294-6
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s15010-019-01294-6